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AbstrACt
Introduction Patients with adrenal insufficiency have 
impaired health-related quality of life (QoL). The dual-
release hydrocortisone preparation, Plenadren, has been 
developed to mimic the physiological cortisol release 
more closely than conventional hydrocortisone treatment. 
Plenadren has been shown to improve QoL, in particular 
fatigue, in patients with primary adrenal insufficiency. 
However, the effect has not been investigated in patients 
with secondary adrenal insufficiency; furthermore, no 
study has taken the diurnal variation of fatigue into 
account. To assess diurnal variations, it is necessary to 
use repeated daily measurements, such as ecological 
momentary assessments (EMAs). This study aims to 
evaluate EMAs of fatigue as outcome in future large-scale 
randomised clinical trials.
Methods and analysis The PlenadrEMA trial is an 
investigator-initiated open-label switch pilot trial of the 
effect of Plenadren versus conventional hydrocortisone on 
fatigue in patients with secondary adrenal insufficiency. 
The trial will include 30 participants. After 5 weeks on their 
usual hydrocortisone treatment, patients will be shifted 
to Plenadren for 16 weeks. Fatigue will be assessed 
using momentary versions of the Multidimensional 
Fatigue Inventory (MFI-20). Items will be administered 
to participants via a smartphone application four times 
daily during 20 days. Assessments will be performed 
before treatment shift and repeated after 12.5 weeks on 
Plenadren. The study will identify the best suited outcome 
for future randomised clinical trials, and in addition, 
estimate the variability and difference in fatigue between 
the two treatments to perform power calculations.
Ethics and dissemination The trial will be conducted in 
accordance with the Declaration of Helsinki and has been 
approved by the Regional Scientific Ethical Committee in 
Copenhagen (ID: H-1-2014-073). All patients will receive 
written and verbal information about the trial and will 
give informed consent before enrolment. Findings will 
be published in peer-reviewed journals and presented at 
international conferences.
trial registration number EudraCT201400203932.
IntroduCtIon
Adrenal insufficiency is a rare, but life-threat-
ening disease in which the adrenal produc-
tion of glucocorticoid is reduced. It can 
be caused by primary adrenal failure or 
secondary adrenal insufficiency due to 
impairment of the hypothalamic–pituitary 
axis. Since the 1950s, patients with adrenal 
insufficiency have been treated with glucocor-
ticoid replacement, and for the last decades 
the standard treatment has been hydrocorti-
sone. For treating adults an oral administra-
tion of 15–25 mg hydrocortisone per day is 
recommended.1 2 Usually, the replacement 
regimen is divided into two to three daily 
doses with a higher dose on waking and the 
smallest dose in the afternoon/evening, in an 
attempt to mimic the physiological rhythm 
of cortisol.1 3–5 Despite optimised regimens, 
it has, however, been clear to most clinicians 
that this replacement regimen is far from 
optimal in terms of many factors including 
mortality and important aspects of quality of 
strengths and limitations of this study
 ► The study employs a novel and innovative 
measurement technology applicable to many other 
patient groups.
 ► The study will become the first to provide an 
outcome for assessing diurnal variations of fatigue 
in clinical trials.
 ► Future power calculations for large-scale 
randomised clinical trials can be conducted on a 
well-informed basis.
 ► Because the study is a pilot study testing the 
outcomes, technology and measurement properties, 
it is neither blinded nor randomised.
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life (QoL) such as fatigue.4 6 7 Hydrocortisone has a short 
plasma half-life of 1.7 hours, often resulting in unde-
tectable levels in the morning and a steep rise after the 
first dose, followed by very low levels by mid-afternoon. 
Thus, patients treated with the conventional replace-
ment regimen characteristically have higher fatigue level 
at certain times during the day. A possible explanation 
is the suboptimal imitation of the physiological rhythm. 
Patients often report sleep disturbances, daytime fatigue 
and early morning fatigue associated with inability to 
undertake employment.4 
To mimic the physiological cortisol rhythm more closely 
a dual-release formulation of hydrocortisone, Plenadren 
was developed. It has been shown to significantly improve 
QoL, particularly fatigue, when measured as secondary 
outcomes of a recent open randomised cross-over trial in 
patients with primary adrenal insufficiency.8 However, it 
is unknown, if a similar effect can be observed in patients 
with secondary adrenal insufficiency due to hypopituita-
rism. Furthermore, no studies have evaluated the effect, 
taking into account the diurnal variation of fatigue.
Recently, a new method of measuring QoL, including 
fatigue has emerged: ecological momentary assessments 
(EMAs). EMA is characterised by repeated sampling of 
real-time experience in the natural environment of the 
patient, allowing both between-subject and intersubject 
analyses including variations over time.9 Thus, it has the 
potential to capture diurnal variations in patient-reported 
outcomes with a high level of reliability and accuracy.
The present study aims to evaluate EMA as outcome in 
future large-scale randomised clinical trials of dual-release 
hydrocortisone, furthermore, to quantify the variability of 
such EMA measurements in patients with adrenal insuffi-
ciency due to hypopituitarism and acquire an estimate of 
the size of the expected difference in scores, both of which 
are required for sample size calculations. Finally, the study 
aims to identify the best suited outcome for a randomised 
clinical trial, that is, the most informative outcome with 
the least participant burden. We hypothesise that dual-re-
lease hydrocortisone will show similar improvements in 
QoL in patients with hypopituitarism as shown in patients 
with primary adrenal insufficiency. Furthermore, we 
hypothesise that the EMA method is highly suitable for 
detecting diurnal variations of fatigue and the changes 
hereof compared with standard questionnaires.
MEthods And AnAlysIs
design
The PlenadrEMA study is an investigator-initiated open-
label switch pilot trial. Included patients will be observed 
for 5 weeks on their usual treatment (two or three times 
daily hydrocortisone). Assessments of QoL, in terms of 
EMA assessments, to be used as baseline measurement in 
the study, will be collected at the beginning of the trial 
period for 20 days preceded by a 5-day technology adap-
tation phase (see figure 1), that is, EMA collection will 
begin on day 6 of the trial period. Thereafter, participants 
will be shifted to dual-release hydrocortisone (Plenadren) 
once daily, on an equivalent dose as per Summary of 
Product Characteristics. Assessments of QoL to be used 
as primary outcome will be performed 12.5 weeks after 
initiation of the intervention treatment, in order to take 
into consideration the period of readjustment of the 
body after the switch from conventional hydrocortisone 
to Plenadren. As done at the baseline observation, 20 
days of EMA measurements will be preceded by a 5-day 
technology adaptation phase (figure 1). At the end of 
the intervention treatment period, the patients will be 
shifted to their usual hydrocortisone treatment and will 
be followed at the outpatient clinic according to the stan-
dard directives of the clinic.
study population
All patients with a diagnosis of adrenal insufficiency due 
to hypopituitarism who are referred to or followed at the 
Department of Endocrinology at Copenhagen University 
Hospital Rigshospitalet will be considered for participa-
tion in this trial. Patients may enter the PlenadrEMA study 
if they comply with the inclusion and exclusion criteria.
Inclusion criteria: age ≥18 years; diagnosis of adrenal 
insufficiency due to hypopituitarism; in steady two or 
three times daily (10–40 mg) hydrocortisone replacement 
treatment; written informed consent; for women: use of 
Figure 1 Study period for an individual participant, total duration: 21 weeks. EMA, ecological momentary assessment. 
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reliable methods of contraception in clinical trials in 
accordance with the definition by the Danish Health and 
Medicines Authority; intrauterine devices or hormonal 
methods (oral contraceptives, contraceptive implants, 
transdermal patches, hormonal vaginal devices or injec-
tions with prolonged release).
Exclusion criteria: pregnancy; breast feeding; acro-
megaly; Cushing’s disease; diabetes mellitus; other major 
confounding disease; known or expected hypersensitivity 
to any of the excipients; lack of compliance (attendance 
and medication).
Given that the method of EMA measurement of fatigue is 
novel, power calculations to determine the correct sample 
size cannot be conducted on a sufficiently informed basis, 
since the magnitude of the expected change and the vari-
ability is unknown. In order to obtain reliable estimates 
of variability and magnitude of expected differences, a 
sample size of N=30 was decided for this pilot study, after 
discussion with an experienced biostatistician. Several 
other pilot studies have investigated EMA for measuring 
symptoms. These studies have included between 19 and 
33 participants,10–15 which corresponds well with our 
chosen sample size.
Intervention
The investigational medicinal product in this study is the 
dual-release hydrocortisone, Plenadren. It is produced 
and delivered by Shire in tablets containing 5 mg and 
20 mg hydrocortisone and will be stored according to 
Summary of Product Characteristics. The initial dose of 
Plenadren is equal to the total daily dose of the patients’ 
usual conventional hydrocortisone. Patients will be 
instructed to take the Plenadren tablets orally in fasting 
state in the morning (between 6:00 and 8:00). The dura-
tion of the intervention period is 16 weeks, including a 
run-in period of 12.5 weeks.
The usual hydrocortisone replacement regimen of the 
patients, that is, conventional hydrocortisone, is used as 
comparator in the trial. Doses include variable combi-
nations of hydrocortisone 20 mg tablets produced by 
TAKEDA and an unlicensed preparation of hydrocorti-
sone 5 mg tablets produced by Glostrup Pharmacy. The 
total dose per day is between 10 and 40 mg and is admin-
istered in two to three daily doses. The individual, usual 
dose of the patient will not be altered on entering the 
trial unless the patient shows clinical symptoms of insuffi-
cient replacement.
Collection of EMA data
In our research group, we have developed a smartphone 
application for collection of EMA data. It follows state-
of-the-art standards for electronic EMA instruments as 
described in the field of EMA research.16 This includes, 
for example, individually adjusted diurnal rhythm, a 
possibility to delay a data entry for up to 1 hour, and time 
stamping of data entries in order to evaluate compliance. 
The EMA application is integrated with the trial manage-
ment system PROgmatic.17 The integrated system handles 
patient flow, electronic case report forms and collection 
of EMA data from mobile devices. EMA data are stored 
on mobile devices and uploaded to a secure, encrypted 
back-end system each night. From here, data are pulled 
also on a nightly basis to PROgmatic, where data complete-
ness can be surveyed in real-time, enabling appropriate 
action to secure data quality, that is, avoid missing data. 
The system is approved by the Danish Data Protection 
Agency (local identifier at Rigshospitalet: 30–1233).
outcome measures
The primary outcome of the study is variability and 
difference in fatigue between conventional and dual-re-
lease hydrocortisone treatment. Fatigue is measured by 
the standardised, validated fatigue instrument: Multidi-
mensional Fatigue Inventory (MFI-20),18 which will be 
adapted to EMA. The MFI-20 is formulated in a way that 
makes it relatively easy to convert into an EMA-measure. 
Four times daily, at semi-randomised time points, the 
participants are prompted by the EMA application to 
respond to eight brief questions from the MFI-20. Four 
items from the General Fatigue scale are administered 
every day during the observation period as well as four 
items from one of the four remaining scales (Physical 
Fatigue, Mental Fatigue, Reduced Activity and Reduced 
Motivation). The reason for administrating only one 
of the four specific scales per day is to reduce response 
burden; thus, these scales are administered in cycles of 
4 days: Physical Fatigue on day 1, Mental Fatigue on day 
2, Reduced Activity on day 3 and Reduced Motivation on 
day 4.
Secondary outcome assessment is specified in table 1 
and includes the standardised, validated questionnaires: 
Fatigue Impact Scale, Addison Disease-specific QoL ques-
tionnaire and the Short Form Health Survey, all of which 
will be administered on visit 2 and 4. Furthermore, blood 
samples, dual-energy X-ray absorptiometry primarily for 
evaluation of body composition, 24 hours blood pres-
sure, salivary cortisol and recording of adverse events 
(AEs) will be assessed as part of the safety evaluation of 
Plenadren on visit 2 and 4. Patients will be asked to pause 
their hydrocortisone treatment and blood samples will 
be collected at least 12 hours after last hydrocortisone 
dosage. Blood samples consist of cholesterol, high-den-
sity lipoprotein cholesterol, low-density lipoprotein 
cholesterol, triglycerides, fasting blood glucose, glycated 
haemoglobin, C reactive protein, electrolytes, fibrinogen, 
plasminogen activator inhibitor-1, cortisol, adrenocorti-
cotropic hormone, cortisol binding globulin, serum type 
1 procollagen and collagen type 1 cross-linked C-telo-
peptide, osteocalcin, receptor activator of nuclear factor 
kappa-B ligand, osteoprotegerin and sclerostin.
biobank
A research biobank of serum and plasma will be estab-
lished for analysis of biochemical markers specified in 
the outcome measures section and for future use. Partici-
pants are informed orally and in writing, and will consent 
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to the withdrawal and storing of biological material. 
Blood samples for the biobank are collected at visit 2 and 
4. Access to material of the biobank for further analysis, 
not included in the study protocol, will require a specific 
authorisation from the Committees of Health Research 
Ethics. The material will be stored according to require-
ments of the Danish Data Protections Agency.
Monitoring
The trial will be monitored by the Good Clinical Practice 
unit at Copenhagen University Hospital.
data and statistical analysis
For each of the two EMA reporting periods, four 
diurnal fatigue profiles are generated for each partici-
pant. Each diurnal fatigue profile consists of four daily 
measurement points. One diurnal profile summarises 
General Fatigue responses during the day across all 
20 days. For each of the other four scales, a profile 
summarising the responses during the day across 
the 5 days they were administered is generated. Scale 
means will be calculated for conventional treatment 
versus dual-release hydrocortisone by mixed models for 
repeated measures. The scale with the largest change in 
score will be selected as the best suited EMA outcome, 
of which difference in mean and SD will be used for 
sample size calculations for future randomised clinical 
trials. Diurnal curves will be generated for the General 
Fatigue scale and inspected as well as statistically tested 
for temporal patterns (mixed models), by dividing 
the day into 3-hour blocks and testing for significant 
variation in scores.19 All analyses will be conducted as 
intention-to-treat analyses, with two-sided significance 
level at 5%.
Patient safety and AE recording
Independent of treatment period, in case of intercur-
rent illness or physical or mental stress, participants will 
be instructed to take additional substitution of imme-
diate release hydrocortisone tablets (rescue medication) 
according to current guidelines. The need for rescue 
medication will be assessed at trial visits according to 
table 1. Participants are questioned about AEs according to 
table 1. In addition, participants are instructed to contact 
their trial contact person if they experience symptoms 
suggestive of AEs. Any identified AE will be registered in 
the case report form of the patient and will be reported to 
the Regional Research Ethics Committee and the Danish 
Health and Medicines Authority according to the Good 
Clinical Practice regulations. When a possible serious 
adverse event (SAE), serious adverse reaction (SAR) or 
suspected unexpected serious adverse reaction (SUSAR) 
is identified, the event will be followed up by the sponsor–
investigator or delegated (medically qualified). Details 
about the event will be sought from the patient’s medical 
record and through direct contact with the patient or rela-
tives (in case of an event leading to death or incapacitation 
of the participant). The event will be assessed for causality 
between Plenadren and the event by the sponsor–investi-
gator or delegated based on a clinical evaluation. Any SAE, 
SAR or SUSAR will be reported as an outcome measure.
Table 1 Timing of data collection
Variable Information visit
Visit 1
(0–1 weeks)
Visit 2
(5 weeks)
Visit 3
(17 weeks)
Visit 4
(21 weeks)
Informed consent x x
Baseline information on current illness 
and medical history
x
Screening blood samples* x
Start-up EMA x x
Shift to Plenadren x
QoL questionnaire:
Fatigue Impact Scale
AddiQoL
SF-36
x x
DEXA-scan x x
24 hours blood pressure x x
Blood samples x x
Salivary cortisol (3 days) x x
Recording of adverse events, adverse 
reactions and the need for rescue 
medication
x x x x
*Screening blood samples corresponds to the annual biochemical assessment in pituitary patients at the Department of Endocrinology, 
Copenhagen University Hospital Rigshospitalet. Fasting is not necessary.
 AddiQoL, Addison Disease-specific quality of life; DEXA, dual-energy X-ray absorptiometry; EMA, ecological momentary assessment; QoL, 
quality of life;  SF-36, Short Form Health Survey.
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EthICs And dIssEMInAtIon
The study will be performed in compliance with the 
Declaration of Helsinki. Inclusion of patients will only 
be carried out after informed consent is obtained. At the 
information visit sponsor–investigator or qualified dele-
gate will provide written and verbal information about the 
study. Participants are given the opportunity of reflection 
for up to 1 week before giving their consent. The original 
signed written informed consent forms are archived at 
the trial site and a copy is given to the participant.
A patient who no longer wishes to participate in the trial, 
can withdraw informed consent at any time without need 
of further explanation, and this will have no consequence 
on the patient’s further treatment. To conduct intention-
to-treat analyses, with as little missing data as possible, the 
investigator or delegate, may ask the patient which aspects 
of the trial he or she wishes to withdraw from. This could 
involve the trial intervention (Plenadren), participation 
in EMA measurement of fatigue, use of already collected 
data in the data analyses or assessment of safety variables. 
The sponsor–investigator shall discontinue a patient from 
the trial intervention at any time, if the patient becomes 
pregnant, experiences intolerable adverse reactions or 
is diagnosed with a major confounding disease during 
the trial period. Dropouts and patients withdrawn from 
the trial by sponsor–investigator will be shifted to their 
usual hydrocortisone treatment and standard follow-up 
at the outpatient clinic. Subjects will not be replaced 
in the trial. Furthermore, in the event that new knowl-
edge about Plenadren may be published that would raise 
profound uncertainty about the safety of the patients, the 
trial will be stopped immediately. Due to the short half-
life of hydrocortisone, specific follow-up for dropouts and 
patients withdrawn from the trial are not required.
The results of this study will be presented at national 
and international conferences as well as to patients and 
clinicians. Results will be submitted for publication in 
peer-reviewed journals.
dIsCussIon
Previous studies have shown improvements in fatigue 
and QoL in patients with primary adrenal insufficiency 
treated with Plenadren.8 20 However, the effect has not yet 
been studied in patients with secondary adrenal insuffi-
ciency due to hypopituitarism. Furthermore, the effect 
has not been investigated taking the diurnal variation 
of fatigue into account. The present study is designed as 
a pilot study with the aim of evaluating feasibility of the 
EMA method for assessing diurnal variations of fatigue, 
quantifying variability and expected difference in EMA 
scores to perform sample size calculations and finally, to 
identify the best suited EMA outcome measure for future 
large-scale randomised clinical trials.
Until the measurement properties have been clarified 
and sample size calculations can be performed on a suffi-
cient foundation, an open-label switch format has been 
chosen instead of conducting a blinded and randomised 
trial. This format has limitations regarding the interpre-
tation of QoL data. To avoid potential placebo effects, 
future studies should be blinded. However, we believe the 
format is well suited to examine diurnal variations for this 
pilot study. Since hydrocortisone replacement is vital to 
patients with adrenal insufficiency washout before treat-
ment switch is not possible. The lack hereof may result in 
carryover effects. However, by including a run-in period 
of 12.5 weeks before collection of EMA and 16 weeks 
before secondary outcomes assessment we aim to mini-
mise such effects.
The coexistence of untreated deficiencies of other pitu-
itary axes could influence the outcome of fatigue during 
treatment of adrenal insufficiency. Most patients in the 
potential study group have verified insufficiencies on 
multiple pituitary axes and receive replacement therapy 
according to common practice. Patients are followed at 
the endocrine outpatient clinic where they are regularly 
tested for pituitary insufficiencies and replacement treat-
ment is initiated if needed. In the present study, the inclu-
sion criteria are not restricted to specific pituitary axes 
(except for adrenal insufficiency), since we aim to inves-
tigate Plenadren and EMA measurements of fatigue in a 
broad patient group rather than to limit the findings to a 
specific subgroup. However, it is recognised that changes 
in replacement therapy during the trial period can affect 
our results, why stable treatment is favoured. In order to 
increase comparability within the patient group, patients 
receiving only the most common hydrocortisone dosages, 
for example, 15–25 mg per day, could be included in the 
study. However, to avoid being unable to reach the sample 
size of 30, the span of daily dosage has been widened to 
10–40 mg per day.
Surveillance of replacement therapy and adjustment of 
doses remain a great challenge for patients and physicians. 
Because no objective assessment has proven reliable, 
monitoring treatment effect is mainly based on clinical 
ground.2 3 An important aspect of the clinical assess-
ment of replacement quality includes evaluation of the 
patients’ subjective well-being, that is, QoL. As described, 
a major complaint in patients treated for adrenal insuffi-
ciency is fatigue. Thus, fatigue is central to assess in the 
clinical evaluation of treatment effect. It is, though, a 
subjective and quite variable concept which can be diffi-
cult to measure. Fatigue, as experienced by patients with 
chronic diseases, has been defined as ‘a general feeling 
of debilitating tiredness or loss of energy’.21 Scientifically, 
fatigue has been conceptualised as a multidimensional 
and subjective construct with a range of aspects, such as 
physical, mental, affective and behavioural.22
For decades, effort has been made to develop respon-
sive instruments in order to assess QoL.18 23 24 However, 
a sophisticated and feasible method responsive to 
changes over short time, such as diurnal variation, is still 
warranted. The EMA method has a great potential for 
assessing such diurnal variation with a high level of sensi-
tivity and reliability. Collecting EMA data electronically 
through a smartphone application is an innovative and 
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novel technology within the field of QoL research and to 
our knowledge no previous study has used this technology 
to assess EMA of fatigue as a primary outcome. A great 
advantage of the application is that it can be installed on 
the patient’s own smartphone, and thus, can easily be 
implemented in everyday life. Fatigue has been shown to 
have substantial impact on patients’ overall QoL. Thus, a 
specific and sensitive instrument is needed to assess the 
effect of interventions with the aim of reducing fatigue 
in patients with chronic diseases. The application possi-
bilities of this EMA method for other patient groups are 
wide. Especially, in monitoring subjective health status 
and treatment effect in other patient groups with diurnal 
variations of fatigue such as patients with rheumatoid 
arthritis, multiple sclerosis, chronic cancer, ischaemic 
heart diseases or renal diseases, this method has great 
potential.
trial status
The first patient visit is scheduled for September 2017. 
Last patient’s last visit is expected in March 2019.
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